An overview of the recent progress in irinotecan pharmacogenetics

Pharmacogenomics

Volumn 11, Issue 3, 2010, Pages 391-406

  Fujiwara, Yutaka ^a   Minami, Hironobu ^b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b NONE

Author keywords

ABCB1; ABCC1; ABCC2; CES; CYP3A4; Ethnicity; Irinotecan; Pharmacogenomics; Polymorphism; SNP; Transporter; UGT

Indexed keywords

BILIRUBIN; CAPECITABINE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 1A1; CARBOXYLESTERASE 1A2; CARBOXYLESTERASE 1A3; CARBOXYLESTERASE 2; CISPLATIN; CYTOCHROME P450 3A4; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG TRANSPORT; ETHNIC DIFFERENCE; EXON; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRON; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHARMACOGENOMICS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ALLELES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CARBOXYLESTERASE; CYTOCHROME P-450 CYP3A; DINUCLEOTIDE REPEATS; DRUG TOXICITY; GENE FREQUENCY; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HOMOZYGOTE; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRODRUGS;

EID: 77949629690     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.19     Document Type: Review

References (96)

1. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25(10), 1157-1164 (1997).
2. Iyer L, King CD, Whitington PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1a1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101(4), 847-854 (1998).
3. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58(3), 468-472 (1998).
4. Garcia-Carbonero R, Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8(3), 641-661 (2002).
5. Iyer L, Hall D, Das S et al.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65(5), 576-582 (1999).
6. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62(3), 608-617 (2002).
7. Jinno H, Tanaka-Kagawa T, Hanioka N et al.: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab. Dispos. 31(1), 108-113 (2003).
8. Fujita K, Ando Y, Nagashima F et al.: Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother. Pharmacol. 60(4), 515-522 (2007).
9. Strassburg CP, Oldhafer K, Manns MP, Tukey RH: Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identifcation of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol. Pharmacol. 52(2), 212-220 (1997).
10. Santos A, Zanetta S, Cresteil T et al.: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6(5), 2012-2020 (2000).
11. Iyer L, Ramirez J, Shepard Dr et al.: Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-defcient mice. Cancer Chemother. Pharmacol. 49(4), 336-341 (2002).
12. De Forni M, Bugat R, Chabot GG et al.: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54(16), 4347-4354 (1994).
13. Kehrer DF, Sparreboom A, Verweij J et al.: Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin. Cancer Res. 7(5), 1136-1141 (2001).
14. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ: Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54(14), 3723-3725 (1994).
15. Mathijssen RH, van Alphen RJ, Verweij J et al.: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7(8), 2182-2194 (2001).
16. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyl- transferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24), 6921-6926 (2000).
17. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2(1), 43-47 (2002).
18. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyl-transferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
19. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91(4), 678-682 (2004).
20. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10(15), 5151-5159 (2004).
21. Kim TW, Innocenti F: Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit. 29(3), 265-270 (2007).
22. Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics 1(1), 15-26 (2000).
23. Mackenzie PI, Bock KW, Burchell B et al.: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15(10), 677-685 (2005).
24. Tukey RH, Strassburg CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616 (2000).
25. Guillemette C: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3(3), 136-158 (2003).
26. Aono S, Yamada Y, Keino H et al.: Identifcation of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem. Biophys. Res. Commun. 197(3), 1239-1244 (1993).
27. Aono S, Yamada Y, Keino H et al.: A new type of defect in the gene for bilirubin uridine 5́-diphosphate-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type I. Pediatr. Res. 35(6), 629-632 (1994).
28. Aono S, Adachi Y, Uyama E et al.: Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 345 (8955), 958-959 (1995).
29. Bosma PJ, Chowdhury JR, Bakker C et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333(18), 1171-1175 (1995).
30. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95(14), 8170-8174 (1998).
31. Sugatani J, Yamakawa K, Yoshinari K et al.: Identifcation of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292(2), 492-497 (2002).
32. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B: Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347(9001), 578-581 (1996).
33. Innocenti F, Grimsley C, Das S et al.: Haplotype structure of the UDP-glucuronosyl-transferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12(9), 725-733 (2002).
34. Kaniwa N, Kurose K, Jinno H et al.: Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (p229l) found in an African-American. Drug Metab. Dispos. 33(3), 458-465 (2005).
35. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ: Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet. Genomics 15(5), 295-301 (2005).
36. Sai K, Saeki M, Saito Y et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75(6), 501-515 (2004).
37. Han JY, Lim HS, Shin ES et al.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24(15), 2237-2244 (2006).
38. Ki CS, Lee KA, Lee SY et al.: Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin. Chem. 49(12), 2078-2081 (2003).
39. Zhang A, Xing Q, Qin S et al.: Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J. 7(5), 333-338 (2007).
40. Kohle C, Mohrle B, Munzel PA et al.: Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem. Pharmacol. 65(9), 1521-1527 (2003).
41. Yamanaka H, Nakajima M, Katoh M et al.: A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14(5), 329-332 (2004).
42. Carlini LE, Meropol NJ, Bever J et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11(3), 1226-1236 (2005).
43. Saeki M, Saito Y, Jinno H et al.: Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J. 6(1), 63-75 (2006).
44. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T: UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9(8), 845-847 (1998).
45. Huang CS, Luo GA, Huang ML, Yu SC, Yang SS: Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 10(6), 539-544 (2000).
46. Hsieh SY, Wu YH, Lin DY, Chu CM, Wu M, Liaw YF: Correlation of mutational analysis to clinical features in Taiwanese patients with Gilbert's syndrome. Am. J. Gastroenterol. 96(4), 1188-1193 (2001).
47. Akaba K, Kimura T, Sasaki A et al.: Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46(1), 21-26 (1998).
48. Araki K, Fujita K, Ando Y et al.: Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 97(11), 1255-1259 (2006).
49. Maitland ML, Grimsley C, Kuttab-Boulos H et al.: Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J. 6(1), 52-62 (2006).
50. Girard H, Villeneuve L, Court MH et al.: The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos. 34(7), 1220-1228 (2006).
51. Sanoff HK, Sargent DJ, Green EM, Mcleod HL, Goldberg RM: Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J. Clin. Oncol. 27(25), 4109-4115 (2009).
52. Minami H, Sai K, Saeki M et al.: Irinotecan pharmacokinetics/ pharmacodynamics and ugt1a genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics 17(7), 497-504 (2007).
53. Lara PN Jr, Natale R, Crowley J et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG s0124. J. Clin. Oncol. 27(15), 2530-2535 (2009).
54. Cecchin E, Innocenti F, D'andrea M et al.: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fuorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15), 2457-2465 (2009).
55. X and PK/PD dose-fnding study of irinotecan based on UGT1A1*6 and *28 genotyping (UGT0601). J. Clin. Oncol. 27, E14560 (2009).
56. Kim T, Sym S, Lee S, Ryu M et al.: A UGT1A1 genotype-directed Phase I study of irinotecan (CPT-11) combined with fxed dose of capecitabine in patients with metastatic colorectal cancer (MCRC). J. Clin. Oncol. 27(Suppl.), 15S (2009) (Abstract 2554
57. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, Mcleod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
58. Stewart CF, Panetta JC, O'Shaughnessy Ma et al.: UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J. Clin. Oncol. 25(18), 2594-2600 (2007).
59. Hosokawa M: Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13(2), 412-431 (2008).
60. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN: Current progress on esterases: from molecular structure to function. Drug Metab. Dispos. 30(5), 488-493 (2002).
61. Xie M, Yang D, Liu L, Xue B, Yan B: Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specifcity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab. Dispos. 30(5), 541-547 (2002).
62. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms HCE-1 and HCE-2. Cancer Res. 60(5), 1189-1192 (2000).
63. Xu G, Zhang W, Ma MK, McLeod HL: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res. 8(8), 2605-2611 (2002).
64. Fukami T, Nakajima M, Maruichi T et al.: Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet. Genomics 18(10), 911-920 (2008).
65. Marsh S, Xiao M, Yu J et al.: Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84(4), 661-668 (2004).
66. Tanimoto K, Kaneyasu M, Shimokuni T, Hiyama K, Nishiyama M: Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet. Genomics 17(1), 1-10 (2007).
67. Kim SR, Sai K, Tanaka-Kagawa T et al.: Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab. Dispos. 35(10), 1865-1872 (2007).
68. Kubo T, Kim SR, Sai K et al.: Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab. Dispos. 33(10), 1482-1487 (2005).
69. Kehrer DF, Mathijssen RH, Verweij J, De Bruijn P, Sparreboom A: Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 20(14), 3122-3129 (2002).
70. Mathijssen RH, De Jong FA, van Schaik RH et al.: Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl Cancer Inst. 96(21), 1585-1592 (2004).
71. Mathijssen RH, Marsh S, Karlsson MO et al.: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9(9), 3246-3253 (2003).
72. Fukushima-Uesaka H, Saito Y, Watanabe H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23(1), 100 (2004).
73. Sai K, Saito Y, Fukushima-Uesaka H et al.: Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother. Pharmacol. 62(3), 529-537 (2008).
74. Murayama N, Nakamura T, Saeki M et al.: CYP3A4 gene polymorphisms infuence testosterone 6b-hydroxylation. Drug Metab. Pharmacokinet. 17(2), 150-156 (2002).
75. Nakajima M, Fukami T, Yamanaka H et al.: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80(3), 282-297 (2006).
76. Sai K, Kaniwa N, Itoda M et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13(12), 741-757 (2003).
77. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y: Multispecifc organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281(1), 304-314 (1997).
78. Chu XY, Kato Y, Sugiyama Y: Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57(10), 1934-1938 (1997).
79. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33(3), 434-439 (2005).
80. Xiang X, Jada SR, Li HH et al.: Pharmacogenetics of SLCO1B1 gene and the impact of *1B and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet. Genomics 16(9), 683-691 (2006).
81. Takane H, Miyata M, Burioka N et al.: Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther. Drug Monit. 29(5), 666-668 (2007).
82. Han JY, Lim HS, Shin ES et al.: Infuence of the organic anion-transporting polypeptide 1b1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59(1), 69-75 (2008).
83. Takane H, Kawamoto K, Sasaki T et al.: Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother. Pharmacol. 63(6), 1165-1169 (2009).
84. Innocenti F, Kroetz DL, Schuetz E et al.: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27(16), 2604-2614 (2009).
85. Noda K, Nishiwaki Y, Kawahara M et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85-91 (2002).
86. Funke S, Brenner H, Chang-Claude J: Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9(8), 1079-1099 (2008).
87. Yamamoto N, Takahashi T, Kunikane H et al.: Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin. Pharmacol. Ther. 85(2), 149-154 (2009).
88. Toffoli G, Cecchin E, Gasparini G et al.: Genotype-driven Phase I study of irinotecan administered in combination with fuorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(5), 866-871 (2009).
89. Toffoli G, Cecchin E, Corona G et al.: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24(19), 3061-3068 (2006).
90. Rouits E, Charasson V, Petain A et al.: Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 99(8), 1239-1245 (2008).
91. Cote JF, Kirzin S, Kramar A et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13(11), 3269-3275 (2007).
92. Mcleod HL, Parodi L, Sargent DJ, Marsh S et al.: UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741. J. Clin. Oncol. 24(18S), 3520 (2006).
93. Massacesi C, Terrazzino S, Marcucci F et al.: Uridine diphosphate glucuronosyl transferase 1a1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106(5), 1007-1016 (2006).
94. Chiara S, Serra M, Marroni P, Lastraioli S, Ponzanelli A, Tomasello L: UGT1A1 promoter genotype and toxicity in patients with advanced colorectal cancer treated with irinotecan-containing chemotherapy. J. Clin. Oncol. 23(16S), 2016 (2005).
95. Pillot GA, Read WL, Hennenfent Kl et al.: A Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: fnal report. J. Thorac. Oncol. 1(9), 972-978 (2006).
96. Rhodes KE, Zhang W, Yang D et al.: ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with frst-line irinotecan. Drug Metab. Lett. 1(1), 23-30 (2007).